The AZA-PD Trial (azathioprine)
Dr Williams-Gray’s team at the University of Cambridge’s Centre for Parkinson-Plus are conducting a clinical trial of azathioprine (AZA-PD), a medication already used to treat inflammation by dampening down the immune system’s response, with the aim of slowing brain cell damage and slowing the progression of Parkinson’s….
The AIM-PD trial (ambroxol)
Supported by Cure Parkinson’s, Van Andel Institute and the John Black Foundation, the next phase of this trial programme will follow shortly. Phase ll of the ‘AIM-PD’ study was a proof of concept study and involved 20 people with the genetic form of Parkinson’s over a 24…
The ADepT-PD trial (nortriptyline)
This trial is recruiting 408 people in 30 centres across the UK. Funded by the NIHR with support from Cure Parkinson’s, the trial lead is Professor Anette Schrag, the Royal Free Hospital, London. ADEPT-PD Antidepressants Trial in Parkinson’s Disease (ADepT-PD): A randomised placebo-controlled trial on…
The UP-Study trial (UDCA)
This trial is now complete. Supported by Cure Parkinson’s and the J P Moulton Foundation, the results are expected in 2021. Originally used to treat cirrhosis of the liver, researchers found that the rescue effect of UDCA on the liver cells may actually be due…
The Bydureon (exenatide) phase 3 trial
Cure Parkinson’s is delighted to be supporting two sub-studies within the Bydureon phase 3 trial which has begun recruiting from six sites in the UK. This phase 3 efficacy trial in a larger cohort is the next stage in a programme of trials and research…